Ignite Creation Date:
2024-05-06 @ 6:25 PM
Last Modification Date:
2024-10-26 @ 2:47 PM
Study NCT ID:
NCT05653180
Status:
RECRUITING
Last Update Posted:
2023-04-03
First Post:
2022-12-06
Brief Title:
IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
Sponsor:
Innovent Biologics Suzhou Co Ltd
Organization:
Innovent Biologics Suzhou Co Ltd
Study Overview
Official Title:
A Single ArmMulti-centerPhase IbII Clinical Study Evaluating IBI310 Combined With Sintilimab in Patients With Advanced Biliary Tract CanceBTC
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This research study is designed to establish whether the combination of IBI310 Sintilimab has efficacy in patients with advanced BTC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None